Patterns of Prophylactic Antiseizure Medication Use in Stroke Patients Admitted to a Neurocritical Care Unit
Halle Escher1, Maysaa Basha2, Eric Nicolau1, Wazim Mohamed2
1Wayne State University School of Medicine, 2Wayne State University, Detroit Medical Center
Objective:

To identify determinants of Prophylactic Antiseizure Medication (pASM) use in the Neurocritical Care Unit (NICU) following strokes. 

Background:

Although use of pASM after subarachnoid hemorrhage (aSAH), intracerebral hemorrhage (ICH), or acute ischemic stroke (AIS) is not recommended, it is often initiated in stroke patients. Factors influencing this practice remain unclear.

Design/Methods:
A retrospective chart review of stroke patients admitted to the NICU over two years was performed. Demographics, stroke subtype, use of pASM, and surgical interventions (SI) were collected. Parametric and non-parametric analyses were conducted.
Results:

Of 235 patients screened, 174 were included in the analysis; 67 (38.5%) of which were started on pASM. Stroke subtypes included AIS (47.7%), ICH (33.9%), and aSAH (18.4%).

Patients started on pASM were younger (median age = 59 years, IQR 52-68 vs 65 years, IQR 56-75; p=0.002) and had lower median GCS (12 vs 14, p=0.01). Use of pASM was more common in hemorrhagic strokes (67% vs 7.2%, p<0.001); and among hemorrhagic, mostly in aSAH (87.5% vs 55.9%, p=0.002).  

pASM use was highest in global pathology (86.4%) vs lobar (35.4%, p<0.0001), infratentorial (31.3%, p<0.0001), and deep (28.6%, p<0.0001). Notably, most patients with SI were started on pASMs: hemicraniectomy (82.4%), EVD insertion (72%), hematoma evacuation (95.5%), and aneurysm clipping (100%).  

ICU and hospital length of stay (LOS) were significantly longer in the pASM group (p< 0.0001) and 5.2% of patients were discharged on pASM.  

Multivariable regression demonstrated SI as the strongest predictor of pASM use (OR 10.56, 95% CI 3.66–30.47, p<0.001). Non-hemorrhagic (OR 0.07, 95% CI 0.03–0.19, p<0.001) and non-global location of strokes (OR 0.56, 95% CI 0.32–0.97, p=0.04) were less likely to receive pASM.

Conclusions:

Use of pASM was highest in aSAH and global pathology, strongly linked to SI, and associated with prolonged LOS. These findings demonstrate the need for better alignment with evidence-based guidelines.

10.1212/WNL.0000000000215256
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.